ABL1 is altered in 0.47% of indolent non-hodgkin lymphoma patients [2].

ABL1 is an inclusion eligibility criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

AFF1 is an inclusion eligibility criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains AFF1 status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ASXL1 is altered in 3.3% of indolent non-hodgkin lymphoma patients [2].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ASXL1 status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BCL2 is an inclusion eligibility criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCL2 status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BCL6 is altered in 1.9% of indolent non-hodgkin lymphoma patients [2].

BCL6 is an inclusion eligibility criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BCR is altered in 1.0% of indolent non-hodgkin lymphoma patients [2].

BCR is an inclusion eligibility criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCR status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

DEK is an inclusion eligibility criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains DEK status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ELL is an inclusion eligibility criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ELL status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is altered in 2.84% of indolent non-hodgkin lymphoma patients [2].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KMT2A is altered in 3.32% of indolent non-hodgkin lymphoma patients [2].

KMT2A is an inclusion eligibility criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MECOM is altered in 6.67% of indolent non-hodgkin lymphoma patients [2].

MECOM is an inclusion eligibility criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLLT1 status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLLT10 status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLLT3 status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLLT4 status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MYC is altered in 0.47% of indolent non-hodgkin lymphoma patients [2].

MYC is an inclusion eligibility criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NRIP3 status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NUP214 is an inclusion eligibility criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NUP214 status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RPN1 status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RUNX1 is altered in 1.42% of indolent non-hodgkin lymphoma patients [2].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TP53 is altered in 9.0% of indolent non-hodgkin lymphoma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].